FOUNDATIONONE®LIQUID CDx

PATIENT
Shih, Hsien-Wei

TUMOR TYPE
Pancreas cancer (NOS)
COUNTRY CODE
TW

REPORT DATE
04 June 2023
ORDERED TEST #
ORD-1638962-01

ABOUT THE TEST FoundationOne®Liquid CDx is a next generation sequencing (NGS) assay that identifies clinically relevant genomic alterations in circulating cell-free DNA.

PATIENT
DISEASE Pancreas cancer (NOS)
NAME Shih, Hsien-Wei
DATE OF BIRTH 14 January 1973
SEX Male
MEDICAL RECORD # 46790652

PHYSICIAN
ORDERING PHYSICIAN Yeh, Yi-Chen
MEDICAL FACILITY Taipei Veterans General Hospital
ADDITIONAL RECIPIENT None
MEDICAL FACILITY ID 205872
PATHOLOGIST Not Provided

SPECIMEN
SPECIMEN ID HWS 1/14/1973
SPECIMEN TYPE Blood
DATE OF COLLECTION 24 May 2023
SPECIMEN RECEIVED 26 May 2023

Biomarker Findings

Blood Tumor Mutational Burden - 0 Muts/Mb
Microsatellite status - MSI-High Not Detected
Tumor Fraction - Elevated Tumor Fraction Not Detected

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

STK11 deletion exon 1
KRAS G12D
RB1 splice site 1814+2T>A
TP53 R273H, P250L

Report Highlights

- Targeted therapies with potential clinical benefit **approved in another tumor type**: **Everolimus** (p. 10), **Temsirolimus** (p. 10)
- Evidence-matched **clinical trial options** based on this patient's genomic findings: (p. 11)

BIOMARKER FINDINGS

Blood Tumor Mutational Burden -
0 Muts/Mb

Microsatellite status -
MSI-High Not Detected

Tumor Fraction -
Elevated Tumor Fraction Not Detected

THERAPY AND CLINICAL TRIAL IMPLICATIONS

No therapies or clinical trials. See Biomarker Findings section

MSI-High not detected. No evidence of microsatellite instability in this sample (see Appendix section).

Tumor fraction is considered elevated when ctDNA levels are high enough that aneuploidy can be detected. The fact that elevated tumor fraction was not detected in this specimen indicates the possibility of lower levels of ctDNA but does not compromise confidence in any reported alterations. However, in the setting of a negative liquid biopsy result, orthogonal testing of a tissue specimen should be considered if clinically indicated (see Biomarker Findings section).

GENOMIC FINDINGS		VAF%	THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)
STK11 -	deletion exon 1	0.35%	None	Everolimus Temsirolimus
8 Trials see p. 13				
KRAS -	G12D	0.37%	None	None
10 Trials see p. 11				

Electronically signed by Brennan Decker, M.D., Ph.D. | 04 June 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the therapies listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and/or exhaustive. Neither the therapies nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies. Therapies contained in this report may have been approved by the US FDA or other national authorities; however, they might not have been approved in your respective country. In the appropriate clinical context, germline testing of *APC*, *ATM*, *BAP1*, *BRCA1*, *BRCA2*, *BRIP1*, *CHEK2*, *FH*, *FLCN*, *MEN1*, *MLH1*, *MSH2*, *MSH6*, *MUTYH*, *NF1*, *NF2*, *PALB2*, *PMS2*, *POLE*, *PTEN*, *RAD51C*, *RAD51D*, *RB1*, *RET*, *SDHA*, *SDHB*, *SDHC*, *SDHD*, *SMAD4*, *STK11*, *TGFBR2*, *TP53*, *TSC1*, *TSC2*, *VHL*, and *WT1* is recommended.

Variant Allele Frequency is not applicable for copy number alterations.



HISTORIC PATIENT FINDINGS		ORD-1638962-01 VAF%
Blood Tumor Mutational Burden		0 Muts/Mb
Microsatellite status		MSI-High Not Detected
Tumor Fraction		Elevated Tumor Fraction Not Detected
STK11	deletion exon 1	0.35%
KRAS	● G12D	0.37%
RB1	● splice site 1814+2T>A	0.48%
TP53	● R273H	0.13%
	● P250L	0.34%

IMPORTANT NOTE This comparison table refers only to genes and biomarkers assayed by prior FoundationOne®Liquid CDx or FoundationOne®CDx tests. Up to five previous tests may be shown.

For some genes in FoundationOne Liquid CDx, only select exons are assayed. Therefore, an alteration found by a previous test may not have been confirmed despite overlapping gene lists. Please refer to the Appendix for the complete list of genes and exons assayed. Variants reported for prior time points reflect reporting practices at the time of the historical test(s). Changes in variant reporting nomenclature, classification, or handling may result in the appearance of discrepancies across time points. The gene and biomarker list will be updated periodically to reflect new knowledge about cancer biology.

As new scientific information becomes available, alterations that had previously been listed as Variants of Unknown Significance (VUS) may become reportable or reportable variants may become VUS.

Tissue Tumor Mutational Burden (TMB) and blood TMB (bTMB) are estimated from the number of synonymous and non-synonymous single-nucleotide variants (SNVs) and insertions and deletions (indels) per area of coding genome sampled, after the removal of known and likely oncogenic driver events and germline SNPs. Tissue TMB is calculated based on variants with an allele frequency of ≥5%, and bTMB is calculated based on variants with an allele frequency of ≥0.5%.

Not Tested = not baited, not reported on test, or test preceded addition of biomarker or gene

Not Detected = baited but not detected on test

Detected = present (VAF% is not applicable)

VAF% = variant allele frequency percentage

Cannot Be Determined = Sample is not of sufficient data quality to confidently determine biomarker status

Please note that other aspects of this table may have changed from the previous version to reflect the most up-to-date reporting information.

Electronically signed by Brennan Decker, M.D., Ph.D. | 04 June 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

BIOMARKER

Blood Tumor Mutational Burden

RESULT
0 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in solid tumors, increased blood tumor mutational burden (bTMB) may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1[1-3], anti-PD-1[3-4], anti-PD-1/CTLA4 therapies[5-6] , anti-PD-L1/CTLA4 therapies[7-10]. A Phase 2 multi-solid-tumor trial showed that bTMB ≥16 Muts/Mb (as measured by this assay) was associated with improved survival from treatment with a PD-1 inhibitor alone or in combination with a CTLA-4 inhibitor[5]. In non-small cell lung cancer (NSCLC), multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single-agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 Muts/Mb-16 Muts/Mb[1,8-10]. In head and neck squamous cell carcinoma (HNSCC), a Phase 3 trial showed that bTMB ≥16 Muts/Mb (approximate equivalency ≥8 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD-L1 inhibitor alone or in combination with a CTLA-4 inhibitor[11]. In colorectal cancer (CRC), a Phase 2 study showed that bTMB TMB ≥28 Muts/Mb (approximate equivalency ≥14 Muts/Mb as measured by this assay) was associated with improved OS from a PD-L1 inhibitor alone or in combination with a CTLA-4 inhibitor[7].

FREQUENCY & PROGNOSIS

Average bTMB levels in solid tumors other than NSCLC have not been evaluated (PubMed, Mar 2023). Published data investigating the prognostic implications of bTMB levels in pancreatic carcinoma are limited (PubMed, Jul 2022). A study of patients with pancreatic ductal adenocarcinoma harboring mismatch repair gene mutations reported improved prognosis for patients with high TMB measured in tissue samples (defined as >50 mutations; survival 69-314 months) compared to those with lower TMB (average of 5.7 mutations; 10-42 months)[12].

FINDING SUMMARY

Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma[13-14] and cigarette smoke in lung cancer[15-16], treatment with temozolomide-based chemotherapy in glioma[17-18], mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes[19-23], and microsatellite instability (MSI)[19,22-23]. High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents[1-2,4]. Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered.

BIOMARKER

Tumor Fraction

RESULT
Elevated Tumor Fraction Not Detected

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Specimens with elevated tumor fraction values have high circulating-tumor DNA (ctDNA) content, and thus higher sensitivity for identifying genomic alterations. Such specimens are at a lower risk of false negative results. However, if elevated tumor fraction is not detected, it does not exclude the presence of disease burden or compromise the confidence of reported alterations. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management[24-29].

FREQUENCY & PROGNOSIS

Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3)[30]. Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer[31], Ewing sarcoma and osteosarcoma[32], prostate cancer[27], breast cancer[33], leiomyosarcoma[34], esophageal cancer[35], colorectal cancer[36], and gastrointestinal cancer[37].

FINDING SUMMARY

Tumor fraction provides an estimate of the percentage of ctDNA present in a cell-free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single-nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content[38], the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy[39-40].

Electronically signed by Brennan Decker, M.D., Ph.D. | 04 June 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
STK11

ALTERATION
deletion exon 1

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Increased mTOR signaling is present in LKB1-deficient tumors, suggesting therapies targeting mTOR may be relevant for tumors with STK11 alterations[41-44]. Case studies have reported PRs for 2 patients with STK11-mutated pancreatic cancer following treatment with the mTOR inhibitor everolimus[45], with 1 PR observed for a patient with Peutz-Jeghers syndrome for 9 months[45]. However, for patients with endometrial carcinoma, LKB1 (STK11) protein levels were not significantly correlated with response to everolimus[46]. Glutaminase inhibitors targeting GLS1 are under investigation for patients with STK11-mutated tumors[47]. Although 50% (1/2) of patients with STK11-mutated advanced NSCLC experienced an SD of 6 months with the GLS1 inhibitor IPN60090, 100% (2/2) of patients with ovarian cancers did not derive clinical benefit from this therapy[47], and preclinical evidence for this targeted approach is conflicting[48-51].

FREQUENCY & PROGNOSIS

STK11 mutations have been reported in up to 2.8% of pancreatic adenocarcinomas analyzed in the TCGA dataset[52-54] and in 1-4% of pancreatic carcinoma cases in other studies[55-57]. LKB1 protein expression has been reported to be reduced or absent in 7-20% of pancreatic adenocarcinomas[55-57]. The association between reduced LKB1 protein and prognosis in patients with pancreatic cancer is not clear[57-58]. Patients with Peutz-Jeghers syndrome have been found to have an increased risk for pancreatic cancer, and studies using mouse models have implicated loss of STK11 or LKB1 inhibition in the development of pancreatic cancer[56,59-62].

FINDING SUMMARY

The serine/threonine kinase STK11 (also called LKB1) activates AMPK and negatively regulates the mTOR pathway in response to changes in cellular energy levels[41]. LKB1 acts as a tumor suppressor in cancer, as loss of function promotes proliferation and tumorigenesis[63-64]. Alterations such as seen here may disrupt STK11 function or expression[65-77].

POTENTIAL GERMLINE IMPLICATIONS

Germline mutations in STK11 underlie Peutz-Jeghers syndrome (PJS), a rare autosomal dominant disorder associated with a predisposition for tumor formation[78]. This disorder has an estimated frequency between 1:29,000 and 1:120,000, although reported rates in the literature vary greatly[78-80]. Although gastrointestinal tumors are the most common malignancies associated with PJS, patients also exhibit an 18-fold increased risk of developing other epithelial cancers[78-80], and individuals with this syndrome have a 30-50% risk of developing breast cancer[78,80]. Given the association with PJS, in the appropriate clinical context testing for the presence of germline mutations in STK11 is recommended.

GENE
KRAS

ALTERATION
G12D

HGVS VARIANT
NM_004985.3:c.35G>A (p.G12D)

VARIANT CHROMOSOMAL POSITION
chr12:25398284

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Preclinical evidence suggests that KRAS activation may predict sensitivity to MEK inhibitors, such as trametinib, binimetinib, cobimetinib, and selumetinib[81-86]. For patients with pancreatic cancer, MEK inhibitor combinations are under investigation. A Phase 2 study of trametinib with pembrolizumab versus gemcitabine after stereotactic body radiotherapy (SBRT) reported increased median OS (mOS, 14.9 months vs. 12.8 months, HR=0.69) benefit for patients with KRAS-mutated, PD-L1 positive disease[87]. Combination MEK/autophagy inhibitors are also under investigation based on preclinical evidence of increased autophagy downstream of KRAS-mutated pancreatic tumors[88-89]. A heavily pretreated patient with pancreatic cancer treated with trametinib plus hydroxychloroquine experienced a PR[88]. A Phase 2 study of the reoviral agent pelareorep with gemcitabine for patients with pancreatic cancer reported 1 PR, 23 SDs, and 5 PDs for 34 patients with a favorable median OS of 10.2 months[90]. A Phase 1b study of second-line pelareorep with pembrolizumab and chemotherapy reported 1 PR of 17.4 months and a DCR of 30% (3/10)[91]; an earlier study reported no benefit from pelareorep in combination with paclitaxel/carboplatin[92]. Trials combining MEK inhibitors with other targeted therapies, such as EGFR inhibitors[93] or PI3K-AKT pathway inhibitors[94-95], reported no PRs and frequent adverse events for patients with KRAS-mutated pancreatic cancer. Clinical trials combining various MEK inhibitors with gemcitabine reported no additional benefit compared to gemcitabine alone irrespective of KRAS mutation status[96-99], despite promising results in earlier trials of MEK inhibitor monotherapies[100-105]. In a Phase 1 study evaluating the MEK-pan-RAF dual inhibitor CH5126766, 6 patients harboring KRAS mutations experienced PRs, including 3 with non-small cell lung cancer (NCSLC), 1 with low-grade serous ovarian carcinoma (LGSOC), 1 with endometrial adenocarcinoma, and 1 with multiple myeloma[106]. Combination of CH5126766 with the FAK inhibitor defactinib elicited PR rates of 50% (4/8) for patients with KRAS-mutated LGSOC and 12% (2/17) for patients with KRAS-mutated NSCLC in a Phase 1 study[107-108] . Preclinical and clinical data suggest that KRAS mutations may predict clinical benefit from SHP2 inhibitors[109-110]. A Phase 1 study of RMC-4630 for relapsed/refractory solid tumors reported a DCR of 58% (23/40) for patients with NSCLC and KRAS mutations and a DCR of 75% (12/16) for patients with NSCLC and KRAS G12C mutations[111]. Interim results from a Phase 1/2 study of RMC-4630 plus cobimetinib reported tumor reduction in 3 of 8 patients with KRAS-mutated colorectal cancer[112]. Preclinical studies suggest that KRAS activating mutations may confer sensitivity to SOS1 inhibitors such as BI-3406, MRTX0902, BI-1701963, and BAY-293 as single agents[113-118] or in combination with covalent KRAS G12C inhibitors[118] and MEK inhibitors[119-120]. Preclinical and clinical data suggest that KRAS G12D mutations may predict clinical benefit from KRAS G12D-targeted, T-cell-receptor-based adoptive cell therapy[121-123]. Case studies of KRAS G12D-targeted, T-cell-receptor-based adoptive cell therapy have reported PRs for pretreated patients with metastatic pancreatic adenocarcinoma[121] or colorectal cancer (CRC)[122]. Preclinical data suggests that KRAS G12D mutations may predict sensitivity to KRAS G12D small-molecule inhibitors, such as MRTX1133[124-128] and RMC9805[129].

FREQUENCY & PROGNOSIS

KRAS mutations have been observed in 91-95% of pancreatic ductal adenocarcinoma cases[52,130], with the majority of mutations found at codon 12[131-134]. KRAS mutations, particularly G12D, have been associated with decreased median survival time in patients with pancreatic ductal adenocarcinoma[132].

FINDING SUMMARY

KRAS encodes a member of the RAS family of small GTPases. Activating mutations in RAS genes can cause uncontrolled cell proliferation and tumor formation[82,135]. KRAS alterations affecting amino acids G12, G13, Q22, P34, A59, Q61, and A146, as well as mutations G10_A11insG, G10_A11insAG (also reported as G10_A11dup and G12_G13insAG), A18D, L19F, D33E, G60_A66dup/E62_A66dup, E62K, E63K, R68S, K117R, and K117N have been characterized as activating and oncogenic[82,136-158].

Electronically signed by Brennan Decker, M.D., Ph.D. | 04 June 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE

RB1

ALTERATION
splice site 1814+2T>A

HGVS VARIANT
NM_000321.2:c.1814+2T>A (p.?)

VARIANT CHROMOSOMAL POSITION
chr13:49027249

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of limited clinical data[159] and strong preclinical data[160-163], RB1 inactivation may be associated with sensitivity to inhibitors of Aurora kinase A, particularly in small cell lung cancer (SCLC). A clinical study evaluating the Aurora kinase A inhibitor alisertib for patients with prostate cancer did not find an association between RB1 deletion and clinical benefit[164]. Other approaches to target RB1 inactivation under investigation in preclinical studies include inhibitors of BCL-2 family members[165] and activation of the NOTCH pathway[166].

FREQUENCY & PROGNOSIS

RB1 mutations have been reported in <1% of pancreatic ductal adenocarcinomas[52-53]. Published data investigating the prognostic implications of RB1 alterations in pancreatic carcinoma are limited (PubMed, Jun 2022). Preclinical data have suggested a role for RB1 inactivation in progression of pancreatic cancer[167-168].

FINDING SUMMARY

RB1 encodes the retinoblastoma protein (Rb), a tumor suppressor and negative regulator of the cell cycle[169-170]. Alterations such as seen here may disrupt RB1 function or expression[171-177].

POTENTIAL GERMLINE IMPLICATIONS

Mutations in RB1 underlie the development of retinoblastoma (RB), a rare tumor that arises at a rate of approximately 1:20,000 live births, with nearly 5,000 new cases worldwide per year[178]. Germline mutations in RB1 account for approximately 40% of RB tumors[179] and are associated with an increased risk of developing secondary malignancies that include soft tissue and bone sarcoma and malignant melanoma[180-181]. In the appropriate clinical context, germline testing of RB1 is recommended.

GENE
TP53

ALTERATION
R273H, P250L

HGVS VARIANT
NM_000546.4:c.818G>A (p.R273H),
NM_000546.4:c.749C>T (p.P250L)

VARIANT CHROMOSOMAL POSITION
chr17:7577120, chr17:7577532

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib[182-185] or p53 gene therapy such as SGT53[186-190]. In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype[191]. A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum-refractory TP53-mutated ovarian, Fallopian tube, or peritoneal cancer[192]. A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum-refractory TP53-mutated ovarian cancer[193]. The combination of adavosertib with paclitaxel and carboplatin for patients with TP53-mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone[194]. In the Phase 2 VIKTORY trial, patients with TP53-mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel[195]. A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations[196]. The Phase 2 FOCUS4-C trial for patients with TP53- and RAS-mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring[197]. In a Phase 1b clinical trial of SGT-53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage[190]. Missense mutations leading to TP53 inactivation may be sensitive to therapies that reactivate mutated p53 such as eprenetapopt. In a Phase 1b trial for patients with p53-positive high-grade serous ovarian cancer, eprenetapopt combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR[198]. A Phase 1 trial of eprenetapopt with pembrolizumab for patients with solid tumors reported an ORR of 10% (3/29)[199].

FREQUENCY & PROGNOSIS

TP53 mutations have been reported in 33-75% of pancreatic carcinomas, with the majority occurring as missense mutations, while deletion of TP53 has been found in 66% of pancreatic ductal adenocarcinoma cases[130,200-202]. TP53 mutations are common in pancreatic ductal adenocarcinomas and are known to occur in the process of pancreatic carcinogenesis[203-204]. Additionally, aberrant expression of p53 has been found in 54-81% of pancreatic ductal adenocarcinoma cases[201,205-207]. Studies have found inconsistent results regarding the prognostic significance of p53 expression in pancreatic ductal adenocarcinoma, although one study correlated low levels of TP53 mRNA with poor patient prognosis[205,208-209].

FINDING SUMMARY

Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers[210]. Alterations such as seen here may disrupt TP53 function or expression[211-215].

POTENTIAL GERMLINE IMPLICATIONS

One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li-Fraumeni syndrome (ClinVar, Apr 2023)[216]. Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li-Fraumeni syndrome and the early onset of many cancers[217-219], including sarcomas[220-221]. Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000[222] to 1:20,000[221]. For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30[223]. In the appropriate clinical context, germline testing of TP53 is recommended.

POTENTIAL CLONAL HEMATOPOIESIS IMPLICATIONS

Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion[224-229]. CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy[224-225]. Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease[230]. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH[228,231-232]. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.

Everolimus

Assay findings association

STK11
deletion exon 1

AREAS OF THERAPEUTIC USE

Everolimus is an orally available mTOR inhibitor that is FDA approved to treat renal cell carcinoma (RCC) following antiangiogenic therapy; pancreatic neuroendocrine tumors; and well-differentiated non-functional neuroendocrine tumors of the lung or gastrointestinal tract. Everolimus is also approved to treat either renal angiomyolipoma or subependymal giant cell astrocytoma in association with tuberous sclerosis complex (TSC). Please see the drug label for full prescribing information.

GENE ASSOCIATION

Based on cases of clinical benefit in pancreatic cancer following everolimus treatment[45,233] , STK11 inactivation may confer sensitivity to mTOR inhibitors.

SUPPORTING DATA

A Phase 1 study for patients with metastatic pancreatic adenocarcinoma reported minimal efficacy for the combination of ribociclib and everolimus with 3/12 SD at 8 weeks as the best response[234]. In some tumor types, including pancreatic cancer, it has been observed that monotherapy with mTOR inhibitors can activate a feedback loop involving the PI3K-AKT pathway, sometimes causing rapid progression of the tumor[235]. Treatment with a dual mTOR and PI3K inhibitor, or with a combination of these inhibitors, may circumvent this phenomenon. In a Phase 1/2 study of patients with advanced pancreatic adenocarcinoma, the combination of everolimus, cetuximab, and capecitabine was found to be excessively toxic with minimal efficacy[236]. Early studies with single-agent everolimus in pancreatic cancer also did not show efficacy[237]; however, clinical trials examining mTOR inhibitors in combination with other chemotherapeutics are underway in pancreatic cancer. Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors[238], a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated >3 months and evaluable patients achieving a median PFS of 6.5 months[239].

Temsirolimus

Assay findings association

STK11
deletion exon 1

AREAS OF THERAPEUTIC USE

Temsirolimus is an intravenous mTOR inhibitor that is FDA approved for the treatment of advanced renal cell carcinoma. Please see the drug label for full prescribing information.

GENE ASSOCIATION

Based on cases of clinical benefit in pancreatic cancer following everolimus treatment[45,233] , STK11 inactivation may confer sensitivity to mTOR inhibitors.

SUPPORTING DATA

A Phase 2 clinical trial in patients with pancreatic cancer reported that temsirolimus monotherapy was ineffective and may have contributed to disease progression[235]. A Phase 1 trial of bevacizumab and temsirolimus plus liposomal doxorubicin in patients with advanced solid tumors showed that the combination was well tolerated and resulted in six-month SD in 21% of patients, with a 21% rate of partial or complete remission[240]. In a Phase 2 clinical trial in non-small cell lung cancer (NSCLC), temsirolimus showed clinical benefit, but further studies are warranted[241]. A Phase 2 study of temsirolimus in patients with KRAS-mutant colorectal cancer reported limited efficacy; however, all patients who exhibited tumor reduction were found to have low levels of mutated KRAS in plasma samples[242]. A Phase 2 clinical trial in patients with pancreatic cancer reported that temsirolimus monotherapy had limited efficacy, and may have contributed to disease progression[235]. A study examining the efficacy of temsirolimus-involving regimens in 24 patients with mesenchymal/metaplastic breast cancer (MpBCs) reported 2 CRs, 4 PRs, 2 instances of SD longer than 6 months, and 4 instances of SD shorter than 6 months[243].

NOTE Genomic alterations detected may be associated with activity of certain US FDA or other specific country approved therapies; however, the therapies listed in this report may have varied evidence in the patient's tumor type. The listed therapies are not ranked in order of potential or predicted efficacy for this patient or in order of level of evidence for this patient's tumor type. The therapies listed in this report may not be complete and/or exhaustive. Furthermore, the listed therapies are limited to US FDA approved pharmaceutical drug products that are linked to a specific genomic alteration. There may also be US FDA approved pharmaceutical drug products that are not linked to a genomic alteration. Further there may also exist pharmaceutical drug products that are not approved by the US FDA or other national authorities. There may also be other treatment modalities available than pharmaceutical drug products.

IMPORTANT Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. There may also be compassionate use or early access programs available, which are not listed in this report. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials are not ranked in order of potential or predicted efficacy for this patient or in order of level of evidence for this patient's tumor type. Clinical trials listed here may have additional enrollment criteria that may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. However, clinicaltrials.gov does not list all clinical trials that might be available.

GENE
KRAS

ALTERATION
G12D

RATIONALE
Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS-mutant pancreatic cancer. Emerging data suggest patients with KRAS-mutant pancreatic cancer may be sensitive to MEK-pan-RAF dual inhibitors or combination MEK/autophagy inhibitors. Preclinical and clinical evidence suggest that KRAS G12D mutations may confer sensitivity to KRAS G12D-targeted, T-cell-receptor-based adoptive cell therapy, KRAS G12D small-molecule inhibitors, or SOS1 inhibitors.

NCT05533463

PHASE 1

Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

TARGETS
KRAS

LOCATIONS: ShangHai (China)

NCT05438667

PHASE NULL

TCR-T Cell Therapy on Advanced Pancreatic Cancer and Other Solid Tumors

TARGETS
KRAS

LOCATIONS: Guangzhou (China)

NCT04892017

PHASE 1/2

A Safety, Tolerability and PK Study of DCC-3116 in Patients With RAS or RAF Mutant Advanced or Metastatic Solid Tumors.

TARGETS
ULK1, ULK2, MEK

LOCATIONS: Oregon, Massachusetts, New York, Texas, Pennsylvania

NCT05578092

PHASE 1/2

A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

TARGETS
SOS1, KRAS

LOCATIONS: Colorado, Ohio, Tennessee, Maryland, Virginia, Texas

NCT05737706

PHASE 1/2

Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

TARGETS
KRAS

LOCATIONS: Michigan, Massachusetts, New York, Tennessee, Texas, Virginia, Florida

NCT05669482

PHASE 1/2

Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer

TARGETS RAFs, MEK, FAK

LOCATIONS: Missouri, New York, Pennsylvania

NCT03745326

PHASE 1/2

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

TARGETS KRAS

LOCATIONS: Maryland

NCT05194735

PHASE 1/2

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

TARGETS KRAS

LOCATIONS: Texas

NCT03825289

PHASE 1

Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer

TARGETS MEK

LOCATIONS: Utah

NCT04132505

PHASE 1

Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer

TARGETS MEK

LOCATIONS: Texas

GENE
STK11

ALTERATION
deletion exon 1

RATIONALE
Increased mTOR signaling is present in LKB1-deficient tumors, suggesting therapies targeting mTOR may be relevant for tumors with STK11 alterations.

NCT03662412

PHASE 1/2

Study of Sirolimus in Patients With Advanced Pancreatic Cancer

TARGETS
mTOR

LOCATIONS: Hangzhou (China)

NCT03239015

PHASE 2

Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event

TARGETS
EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6

LOCATIONS: Shanghai (China)

NCT04803318

PHASE 2

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

TARGETS
mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK

LOCATIONS: Guangzhou (China)

NCT05125523

PHASE 1

A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors

TARGETS
mTOR

LOCATIONS: Tianjin (China)

NCT03297606

PHASE 2

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

TARGETS
VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, DDR2, KIT, EGFR, PD-1, CTLA-4, PARP, CDK4, CDK6, FLT3, CSF1R, RET, mTOR, ERBB2, MEK, BRAF, SMO

LOCATIONS: Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)

NCT05036226

PHASE 1/2

COAST Therapy in Advanced Solid Tumors and Prostate Cancer

TARGETS
DDR2, ABL, SRC, KIT, mTOR

LOCATIONS: South Carolina

NCT01582191

PHASE 1

A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer

TARGETS
mTOR, EGFR, SRC, RET, VEGFRs

LOCATIONS: Texas

NCT03203525

PHASE 1

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

TARGETS
VEGFA, mTOR

LOCATIONS: Texas

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

ATR
NM_001184.3: c.4654A>G
(p.I1552V)
chr3:142231300

CBL
NM_005188.2: c.1543G>C
(p.A515P)
chr11:119155790

FANCG
NM_004629.1: c.881G>A
(p.G294E)
chr9:35076764

FLT3
NM_004119.2: c.190G>A
(p.G64R)
chr13:28636182

KLHL6
NM_130446.2: c.1182T>A
(p.Y394*)
chr3:183212035

ORDERED TEST # ORD-1638962-01

APPENDIX Genes assayed in FoundationOne®Liquid CDx

FoundationOne Liquid CDx interrogates 324 genes, including 309 genes with complete exonic (coding) coverage and 15 genes with only select non-coding coverage (indicated with an *) ; 75 genes (indicated in bold) are captured with increased sensitivity and have complete exonic (coding) coverage unless otherwise noted.

ABL1 **Exons 4-9**	*ACVR1B*	***AKT1*** **Exon 3**	*AKT2*	*AKT3*	***ALK*** **Exons 20-29, Introns 18, 19**	*ALOX12B*	*AMER1* (FAM123B or WTX)	***APC***
AR	***ARAF*** **Exons 4, 5, 7, 11, 13, 15, 16**	*ARFRP1*	*ARID1A*	*ASXL1*	***ATM***	***ATR***	*ATRX*	*AURKA*
AURKB	*AXIN1*	*AXL*	*BAP1*	*BARD1*	*BCL2*	*BCL2L1*	*BCL2L2*	*BCL6*
BCOR	*BCORL1*	*BCR** Introns 8, 13, 14	***BRAF*** **Exons 11-18,** Introns 7-10	***BRCA1*** Introns 2, 7, 8, 12, 16, 19, 20	***BRCA2*** Intron 2	*BRD4*	*BRIP1*	*BTG1*
BTG2	***BTK*** **Exons 2, 15**	*CALR*	*CARD11*	*CASP8*	*CBFB*	*CBL*	***CCND1***	*CCND2*
CCND3	*CCNE1*	*CD22*	*CD70*	*CD74** Introns 6-8	*CD79A*	*CD79B*	***CD274*** **(PD-L1)**	*CDC73*
CDH1	***CDK12***	***CDK4***	***CDK6***	*CDK8*	*CDKN1A*	*CDKN1B*	***CDKN2A***	*CDKN2B*
CDKN2C	*CEBPA*	*CHEK1*	***CHEK2***	*CIC*	*CREBBP*	***CRKL***	*CSF1R*	*CSF3R*
CTCF	*CTNNA1*	***CTNNB1*** **Exon 3**	*CUL3*	*CUL4A*	*CXCR4*	*CYP17A1*	*DAXX*	*DDR1*
DDR2 **Exons 5, 17, 18**	*DIS3*	*DNMT3A*	*DOT1L*	*EED*	***EGFR*** **Introns 7,** 15, **24-27**	*EMSY* (C11orf30)	*EP300*	*EPHA3*
EPHB1	*EPHB4*	***ERBB2***	***ERBB3*** **Exons 3, 6, 7, 8, 10, 12, 20, 21, 23, 24, 25**	*ERBB4*	*ERCC4*	*ERG*	***ERRFI1***	***ESR1*** **Exons 4-8**
*ETV4** Intron 8	*ETV5** Introns 6, 7	***ETV6**** **Introns 5, 6**	*EWSR1** Introns 7-13	***EZH2*** **Exons 4, 16, 17, 18**	*EZR** Introns 9-11	*FANCA*	*FANCC*	*FANCG*
FANCL	*FAS*	*FBXW7*	*FGF10*	*FGF12*	*FGF14*	*FGF19*	*FGF23*	*FGF3*
FGF4	*FGF6*	***FGFR1*** Introns 1, 5, **Intron 17**	***FGFR2*** Intron 1, **Intron 17**	***FGFR3*** **Exons 7, 9 (alternative designation exon 10), 14, 18, Intron 17**	*FGFR4*	*FH*	*FLCN*	*FLT1*
FLT3 **Exons 14, 15, 20**	***FOXL2***	*FUBP1*	*GABRA6*	*GATA3*	*GATA4*	*GATA6*	*GID4* (C17orf39)	***GNA11*** **Exons 4, 5**
GNA13	***GNAQ*** **Exons 4, 5**	***GNAS*** **Exons 1, 8**	*GRM3*	*GSK3B*	*H3-3A* (H3F3A)	*HDAC1*	*HGF*	*HNF1A*
HRAS **Exons 2, 3**	*HSD3B1*	*ID3*	***IDH1*** **Exon 4**	***IDH2*** **Exon 4**	*IGF1R*	*IKBKE*	*IKZF1*	*INPP4B*
IRF2	*IRF4*	*IRS2*	*JAK1*	***JAK2*** **Exon 14**	***JAK3*** **Exons 5, 11, 12, 13, 15, 16**	*JUN*	*KDM5A*	*KDM5C*
KDM6A	*KDR*	*KEAP1*	*KEL*	***KIT*** **Exons 8, 9, 11, 12, 13, 17,** Intron 16	*KLHL6*	*KMT2A* (MLL) Introns 6, 8-11, Intron 7	*KMT2D* (MLL2)	***KRAS***

APPENDIX Genes assayed in FoundationOne®Liquid CDx

FoundationOne Liquid CDx interrogates 324 genes, including 309 genes with complete exonic (coding) coverage and 15 genes with only select non-coding coverage (indicated with an *) ; 75 genes (indicated in bold) are captured with increased sensitivity and have complete exonic (coding) coverage unless otherwise noted.

LTK	*LYN*	*MAF*	***MAP2K1*** **(MEK1) Exons 2, 3**	***MAP2K2*** **(MEK2) Exons 2-4, 6, 7**	*MAP2K4*	*MAP3K1*	*MAP3K13*	*MAPK1*
MCL1	***MDM2***	*MDM4*	*MED12*	*MEF2B*	*MEN1*	*MERTK*	***MET***	*MITF*
MKNK1	*MLH1*	***MPL*** **Exon 10**	*MRE11* (MRE11A)	*MSH2* Intron 5	*MSH3*	*MSH6*	*MST1R*	*MTAP*
MTOR **Exons 19, 30, 39, 40, 43-45, 47, 48, 53, 56**	*MUTYH*	*MYB** Intron 14	***MYC*** **Intron 1**	*MYCL* (MYCL1)	***MYCN***	***MYD88*** **Exon 4**	*NBN*	***NF1***
NF2	*NFE2L2*	*NFKBIA*	*NKX2-1*	*NOTCH1*	*NOTCH2* Intron 26	*NOTCH3*	***NPM1*** **Exons 4-6, 8, 10**	***NRAS*** **Exons 2, 3**
NSD2 (WHSC1 or MMSET)	*NSD3* (WHSC1L1)	*NT5C2*	***NTRK1*** **Exons 14, 15, Introns 8-11**	*NTRK2* Intron 12	***NTRK3*** **Exons 16, 17**	*NUTM1** Intron 1	*P2RY8*	***PALB2***
PARP1	*PARP2*	*PARP3*	*PAX5*	*PBRM1*	*PDCD1* (PD-1)	***PDCD1LG2*** **(PD-L2)**	***PDGFRA*** **Exons 12, 18, Introns 7, 9, 11**	***PDGFRB*** **Exons 12-21, 23**
PDK1	*PIK3C2B*	*PIK3C2G*	***PIK3CA*** **Exons 2, 3, 5-8, 10, 14, 19, 21 (Coding Exons 1, 2, 4-7, 9, 13, 18, 20)**	*PIK3CB*	*PIK3R1*	*PIM1*	*PMS2*	*POLD1*
POLE	*PPARG*	*PPP2R1A*	*PPP2R2A*	*PRDM1*	*PRKAR1A*	*PRKCI*	*PRKN* (PARK2)	*PTCH1*
PTEN	***PTPN11***	*PTPRO*	*QKI*	*RAC1*	*RAD21*	*RAD51*	*RAD51B*	*RAD51C*
RAD51D	*RAD52*	*RAD54L*	***RAF1*** **Exons 3, 4, 6, 7, 10, 14, 15, 17,** Introns 4-8	*RARA* Intron 2	***RB1***	*RBM10*	*REL*	***RET*** Introns 7, 8, **Exons 11, 13-16, Introns 9-11**
RICTOR	*RNF43*	***ROS1*** **Exons 31, 36-38, 40, Introns 31-35**	*RPTOR*	*RSPO2** Intron 1	*SDC4** Intron 2	*SDHA*	*SDHB*	*SDHC*
SDHD	*SETD2*	*SF3B1*	*SGK1*	*SLC34A2** Intron 4	*SMAD2*	*SMAD4*	*SMARCA4*	*SMARCB1*
SMO	*SNCAIP*	*SOCS1*	*SOX2*	*SOX9*	*SPEN*	*SPOP*	*SRC*	*STAG2*
STAT3	***STK11***	*SUFU*	*SYK*	*TBX3*	*TEK*	*TENT5C* (FAM46C)	*TERC** ncRNA	***TERT**** **Promoter**
TET2	*TGFBR2*	*TIPARP*	*TMPRSS2** Introns 1-3	*TNFAIP3*	*TNFRSF14*	***TP53***	*TSC1*	*TSC2*
TYRO3	*U2AF1*	***VEGFA***	*VHL*	*WT1*	*XPO1*	*XRCC2*	*ZNF217*	*ZNF703*

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Microsatellite (MS) status
Blood Tumor Mutational Burden (bTMB)
Tumor Fraction

Electronically signed by Brennan Decker, M.D., Ph.D. | 04 June 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

FoundationOne Liquid CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium. The CE-IVD regulatory status of FoundationOne Liquid CDx is applicable in countries that accept and/or recognize the CE mark.

CE IVD

ABOUT FOUNDATIONONE LIQUID CDx

FoundationOne Liquid CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne Liquid CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details.

INTENDED USE

FoundationOne Liquid CDx is a next generation sequencing based *in vitro* diagnostic device that analyzes 324 genes. Substitutions and insertion and deletion alterations (indels) are reported in 311 genes, copy number alterations (CNAs) are reported in 310 genes, and gene rearrangements are reported in 324 genes. The test also detects the genomic signatures blood tumor mutational burden (bTMB), microsatellite instability (MSI), and tumor fraction. FoundationOne Liquid CDx utilizes circulating cell-free DNA (cfDNA) isolated from plasma derived from the anti-coagulated peripheral whole blood of cancer patients. The test is intended to be used as a companion diagnostic to identify patients who may benefit from treatment with targeted therapies in accordance with the approved therapeutic product labeling. Additionally, FoundationOne Liquid CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with malignant neoplasms.

TEST PRINCIPLES

The FoundationOne Liquid CDx assay is performed exclusively as a laboratory service using circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole blood from patients with solid malignant neoplasms. The assay employs a single DNA extraction method to obtain cfDNA from plasma from whole blood. Extracted cfDNA undergoes whole-genome shotgun library construction and hybridization-based capture of 324 cancer-related genes including coding exons and select introns of 309 genes, as well as only select intronic regions or non-coding regions of 15 genes. Hybrid-capture selected libraries are sequenced with deep coverage using the NovaSeq® 6000 platform. Sequence data are processed using a customized analysis pipeline designed to accurately detect genomic alterations, including base substitutions, indels, select copy number variants, and select genomic rearrangements. Substitutions and insertion and deletion alterations (indels) are reported in 311 genes, copy number alterations (CNAs) are reported in 310 genes, and gene rearrangements are reported in 324 genes. The assay also reports tumor fraction, and genomic signatures including MSI and bTMB. A subset of targeted regions in 75 genes is baited for increased sensitivity.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. *Note:* A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

QUALIFIED ALTERATION CALLS (EQUIVOCAL)

All equivocal calls, regardless of alteration type, imply that there is adequate evidence to call the alteration with confidence. However, the repeatability of equivocal calls may be lower than non-equivocal calls.

RANKING OF THERAPIES AND CLINICAL TRIALS

Ranking of Therapies in Summary Table

Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

LIMITATIONS

1. For *in vitro* diagnostic use.
2. For prescription use only. This test must be ordered by a qualified medical professional in accordance with clinical laboratory regulations.
3. A negative result does not rule out the presence of a mutation below the limits of detection of the assay. Patients for whom no companion diagnostic alterations are detected should be considered for confirmation with an appropriately validated tumor tissue test, if available.
4. The FoundationOne Liquid CDx assay does not detect heterozygous deletions.
5. The test is not intended to provide information on cancer predisposition.
6. Performance has not been validated for cfDNA input below the specified minimum input.
7. Tissue TMB and blood TMB (bTMB) are estimated from the number of synonymous and nonsynonymous single-nucleotide variants (SNVs) and insertions and deletions (indels) per area of coding genome sampled, after the removal of known and likely oncogenic driver events and germline SNPs. Tissue TMB is calculated based on variants with an allele frequency of ≥5%, and bTMB is calculated based on variants with an allele frequency of ≥0.5%.
8. Tumor fraction is the percentage of circulating tumor DNA (ctDNA) present in a cell-free DNA (cfDNA) sample. The tumor fraction estimate is computationally derived from the observed level of aneuploidy in the sample. Tumor fraction is considered elevated when ctDNA levels are high enough that aneuploidy can be detected and is significantly distinct from that typically found in non-tumor samples.
9. Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the tumor genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor. The MSI algorithm is based on genome wide analysis of 1765 microsatellite loci and not based on the 5 or 7 MSI loci described in current clinical practice guidelines for solid tissue testing.
10. Genomic findings from circulating cell-free DNA (cfDNA) may originate from circulating tumor DNA fragments, germline alterations, or non-tumor somatic alterations, such as clonal hematopoiesis of indeterminate potential (CHIP). Genes with alterations that may be derived from CHIP include, but are not limited to: *ASXL1*, *ATM*, *CBL*, *CHEK2*, *DNMT3A*, *JAK2*,

KMT2D (*MLL2*), *MPL*, *MYD88*, *SF3B1*, *TET2*, *TP53*, and *U2AF1*.

11. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. If a reported alteration is suspected to be germline, confirmatory testing should be considered in the appropriate clinical context.
12. The test is not intended to replace germline testing or to provide information about cancer predisposition.

REPORT HIGHLIGHTS

The Report Highlights includes select genomic and therapeutic information with potential impact on patient care and treatment that is specific to the genomics and tumor type of the sample analyzed. This section may highlight information including targeted therapies with potential sensitivity or resistance; evidence-matched clinical trials; and variants with potential diagnostic, prognostic, nontargeted treatment, germline, or clonal hematopoiesis implications. Information included in the Report Highlights is expected to evolve with advances in scientific and clinical research. Findings included in the Report Highlights should be considered in the context of all other information in this report and other relevant patient information. Decisions on patient care and treatment are the responsibility of the treating physician.

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >30%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM, BAP1, BRCA1, BRCA2, BRIP1, CHEK2, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLE, RAD51C, RAD51D, RET, SDHA, SDHB, SDHC, SDHD, TSC2,* and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1, ATM, CBL, CHEK2, DNMT3A, IDH2, JAK2, KMT2D (MLL2), MPL, MYD88, SF3B1, TET2,* and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne Liquid CDx.

TREATMENT DECISIONS ARE THE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this test or the information contained in this report.

Certain sample of variant characteristics may result in reduced sensitivity. These include: low sample quality, deletions and insertions >40bp, or repetitive/high homology sequences. FoundationOne Liquid CDx is performed using cell-free DNA, and as such germline events may not be reported.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
Muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

REFERENCE SEQUENCE INFORMATION

Sequence data is mapped to the human genome, Genome Reference Consortium Human Build 37 (GRCh37), also known as hg19.

MR Suite Version (RG) 7.9.0

1. Gandara DR, et al. Nat. Med. (2018) pmid: 30082870
2. Wang Z, et al. JAMA Oncol (2019) pmid: 30816954
3. Sturgill EG, et al. Oncologist (2022) pmid: 35274716
4. Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950
5. Schenker et al., 2022; AACR Abstract CT022
6. Saori et al., 2021; ESMO Abstract 80P
7. Chen EX, et al. JAMA Oncol (2020) pmid: 32379280
8. Rizvi NA, et al. JAMA Oncol (2020) pmid: 32271377
9. Si H, et al. Clin Cancer Res (2021) pmid: 33355200
10. Leighl NB, et al. J Thorac Oncol (2022) pmid: 34800700
11. Li et al., 2020; ASCO Abstract 6511
12. Hu et al., 2017; ASCO Abstract e15791
13. Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635
14. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803
15. Pfeifer GP, et al. Oncogene (2002) pmid: 12379884
16. Rizvi NA, et al. Science (2015) pmid: 25765070
17. Johnson BE, et al. Science (2014) pmid: 24336570
18. Choi S, et al. Neuro-oncology (2018) pmid: 29452419
19. Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398
20. Briggs S, et al. J. Pathol. (2013) pmid: 23447401
21. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393
22. Nature (2012) pmid: 22810696
23. Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919
24. Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679
25. Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454
26. Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573
27. Choudhury AD, et al. JCI Insight (2018) pmid: 30385733
28. Goodall J, et al. Cancer Discov (2017) pmid: 28450425
29. Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207
30. Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385
31. Lapin M, et al. J Transl Med (2018) pmid: 30400802
32. Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550
33. Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117
34. Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095
35. Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681
36. Fan G, et al. PLoS ONE (2017) pmid: 28187169
37. Vu et al., 2020; DOI: 10.1200/PO.19.00204
38. Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320
39. Zhang EW, et al. Cancer (2020) pmid: 32757294
40. Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418
41. Shaw RJ, et al. Cancer Cell (2004) pmid: 15261145
42. Ji H, et al. Nature (2007) pmid: 17676035
43. Contreras CM, et al. Cancer Res. (2008) pmid: 18245476
44. Gurumurthy S, et al. Cancer Res. (2008) pmid: 18172296
45. Klümpen HJ, et al. J. Clin. Oncol. (2011) pmid: 21189378
46. Trédan O, et al. Target Oncol (2013) pmid: 23238879
47. Yap et al., 2021; ASCO Abstract 3001
48. Momcilovic M, et al. Cancer Cell (2018) pmid: 29763624
49. Galan-Cobo A, et al. Cancer Res (2019) pmid: 31040157
50. Paik PK, et al. J Thorac Oncol (2022) pmid: 36240971
51. Romero R, et al. Nat. Med. (2017) pmid: 28967920
52. Witkiewicz AK, et al. Nat Commun (2015) pmid: 25855536
53. Bailey P, et al. Nature (2016) pmid: 26909576
54. Cao L, et al. Cell (2021) pmid: 34534465
55. Sahin F, et al. Mod. Pathol. (2003) pmid: 12861065
56. Yee NS, et al. Cancer Biol. Ther. () pmid: 12673116
57. Morton JP, et al. Gastroenterology (2010) pmid: 20452353
58. Bachet JB, et al. Ann. Oncol. (2012) pmid: 22377565
59. Hezel AF, et al. Mol. Cell. Biol. (2008) pmid: 18227155
60. Lo B, et al. J. Cell Biol. (2012) pmid: 23266956
61. Resta N, et al. Dig Liver Dis (2013) pmid: 23415580
62. Shackelford DB, et al. Nat. Rev. Cancer (2009) pmid: 19629071
63. Carretero J, et al. Cancer Cell (2010) pmid: 20541700
64. Ollila S, et al. J Mol Cell Biol (2011) pmid: 21926085
65. Qiu W, et al. Oncogene (2006) pmid: 16407837
66. Mehenni H, et al. Am. J. Hum. Genet. (1998) pmid: 9837816
67. Karuman P, et al. Mol. Cell (2001) pmid: 11430832
68. Baas AF, et al. EMBO J. (2003) pmid: 12805220
69. Zeng PY, et al. Cancer Res. (2006) pmid: 17108107
70. Boudeau J, et al. J. Cell. Sci. (2004) pmid: 15561763
71. Scott KD, et al. Cancer Res. (2007) pmid: 17575127
72. Xie Z, et al. Mol. Cell. Biol. (2009) pmid: 19414597
73. Boudeau J, et al. Hum. Mutat. (2003) pmid: 12552571
74. Forcet C, et al. Hum. Mol. Genet. (2005) pmid: 15800014
75. Zhang L, et al. Sci Rep (2015) pmid: 25960268
76. Berger AH, et al. Cancer Cell (2016) pmid: 27478040
77. Donnelly LL, et al. Carcinogenesis (2021) pmid: 34849607
78. Amos CI, et al. J. Med. Genet. (2004) pmid: 15121768
79. Hearle N, et al. Clin. Cancer Res. (2006) pmid: 16707622
80. van der Groep P, et al. Cell Oncol (Dordr) (2011) pmid: 21336636
81. Nakano H, et al. Proc. Natl. Acad. Sci. U.S.A. (1984) pmid: 6320174
82. Pylayeva-Gupta Y, et al. Nat. Rev. Cancer (2011) pmid: 21993244
83. Yamaguchi T, et al. Int. J. Oncol. (2011) pmid: 21523318
84. Watanabe M, et al. Cancer Sci. (2013) pmid: 23438367
85. Gilmartin AG, et al. Clin. Cancer Res. (2011) pmid: 21245089
86. Yeh JJ, et al. Mol. Cancer Ther. (2009) pmid: 19372556
87. Zhu X, et al. Lancet Oncol (2022) pmid: 35240087
88. Kinsey CG, et al. Nat. Med. (2019) pmid: 30833748
89. Bryant KL, et al. Nat. Med. (2019) pmid: 30833752
90. Mahalingam D, et al. Cancers (Basel) (2018) pmid: 29799479
91. Mahalingam D, et al. Clin. Cancer Res. (2019) pmid: 31694832
92. Noonan AM, et al. Mol. Ther. (2016) pmid: 27039845
93. Ko AH, et al. Clin. Cancer Res. (2016) pmid: 26251290
94. Chung V, et al. JAMA Oncol (2017) pmid: 27978579
95. Bedard PL, et al. Clin. Cancer Res. (2015) pmid: 25500057
96. Van Laethem JL, et al. Target Oncol (2017) pmid: 27975152
97. Infante JR, et al. Eur. J. Cancer (2013) pmid: 23583440
98. Infante JR, et al. Eur. J. Cancer (2014) pmid: 24915778
99. Van Cutsem E, et al. Int. J. Cancer (2018) pmid: 29756206
100. Bodoky G, et al. Invest New Drugs (2012) pmid: 21594619
101. Rinehart J, et al. J. Clin. Oncol. (2004) pmid: 15483017
102. Lorusso PM, et al. J. Clin. Oncol. (2005) pmid: 16009947
103. Infante JR, et al. Lancet Oncol. (2012) pmid: 22805291
104. Weekes CD, et al. Clin. Cancer Res. (2013) pmid: 23434733
105. Garrido-Laguna I, et al. Oncoscience (2015) pmid: 25897431
106. Guo C, et al. Lancet Oncol (2020) pmid: 33128873
107. Krebs et al., 2021; AACR Abstract CT019
108. Shinde et al., 2020; AACR Abstract CT143
109. Lu H, et al. Mol Cancer Ther (2019) pmid: 31068384
110. Mainardi S, et al. Nat Med (2018) pmid: 29808006
111. Koczywas et al., 2021; AACR Abstract LB001
112. Bendell et al., 2020; EORTC-NCI-AACR Abstract 5
113. Hofmann MH, et al. Cancer Discov (2021) pmid: 32816843
114. He H, et al. J Med Chem (2022) pmid: 36173339
115. Zhang S, et al. J Med Chem (2022) pmid: 36384290
116. Liu M, et al. ACS Med Chem Lett (2023) pmid: 36793426
117. Ramharter J, et al. J Med Chem (2021) pmid: 33719426
118. Ketcham JM, et al. J Med Chem (2022) pmid: 35833726
119. Plangger A, et al. Discov Oncol (2022) pmid: 36048281
120. Ma Y, et al. Cancers (Basel) (2022) pmid: 36139627
121. Leidner R, et al. N Engl J Med (2022) pmid: 35648703
122. Tran E, et al. N Engl J Med (2016) pmid: 27959684
123. Wang QJ, et al. Cancer Immunol Res (2016) pmid: 26701267
124. Wang X, et al. J Med Chem (2022) pmid: 34889605
125. Kemp SB, et al. Cancer Discov (2023) pmid: 36472553
126. Hallin J, et al. Nat Med (2022) pmid: 36216931
127. Issahaku AR, et al. Sci Rep (2022) pmid: 36273239
128. Ji X, et al. ACS Omega (2023) pmid: 36844555
129. Jiang et al., 2023; AACR Abstract 526
130. Biankin AV, et al. Nature (2012) pmid: 23103869
131. Feldmann G, et al. J Hepatobiliary Pancreat Surg (2007) pmid: 17520196
132. Rachakonda PS, et al. PLoS ONE (2013) pmid: 23565280
133. Hruban RH, et al. Am. J. Pathol. (1993) pmid: 8342602
134. Maitra A, et al. Best Pract Res Clin Gastroenterol (2006) pmid: 16549325
135. Kahn S, et al. Anticancer Res. () pmid: 3310850
136. Akagi K, et al. Biochem. Biophys. Res. Commun. (2007) pmid: 17150185
137. Bollag G, et al. J. Biol. Chem. (1996) pmid: 8955068
138. Buhrman G, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20194776
139. Sci. STKE (2004) pmid: 15367757
140. Edkins S, et al. Cancer Biol. Ther. (2006) pmid: 16969076
141. Feig LA, et al. Mol. Cell. Biol. (1988) pmid: 3043178
142. Gremer L, et al. Hum. Mutat. (2011) pmid: 20949621
143. Janakiraman M, et al. Cancer Res. (2010) pmid: 20570890
144. Kim E, et al. Cancer Discov (2016) pmid: 27147599
145. Lukman S, et al. PLoS Comput. Biol. (2010) pmid: 20838576
146. Naguib A, et al. J Mol Signal (2011) pmid: 21371307
147. Prior IA, et al. Cancer Res. (2012) pmid: 22589270
148. Privé GG, et al. Proc. Natl. Acad. Sci. U.S.A. (1992) pmid: 1565661
149. Scheffzek K, et al. Science (1997) pmid: 9219684
150. Scholl C, et al. Cell (2009) pmid: 19490892
151. Smith G, et al. Br. J. Cancer (2010) pmid: 20147967
152. Tyner JW, et al. Blood (2009) pmid: 19075190
153. Valencia A, et al. Biochemistry (1991) pmid: 2029511
154. White Y, et al. Nat Commun (2016) pmid: 26854029
155. Wiest JS, et al. Oncogene (1994) pmid: 8058307
156. Angeles AKJ, et al. Oncol Lett (2019) pmid: 31289513

Electronically signed by Brennan Decker, M.D., Ph.D. | 04 June 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

157. Tong JH, et al. Cancer Biol. Ther. (2014) pmid: 24642870
158. Loree JM, et al. Clin Cancer Res (2021) pmid: 34117033
159. Owonikoko et al., 2016; ESMO Abstract 14230
160. Hook KE, et al. Mol. Cancer Ther. (2012) pmid: 22222631
161. Gong X, et al. Cancer Discov (2019) pmid: 30373917
162. Oser MG, et al. Cancer Discov (2019) pmid: 30373918
163. Yang W, et al. Kaohsiung J Med Sci (2022) pmid: 34741392
164. Beltran H, et al. Clin. Cancer Res. (2019) pmid: 30232224
165. Allaman-Pillet N, et al. Ophthalmic Genet. () pmid: 21955141
166. Viatour P, et al. J. Exp. Med. (2011) pmid: 21875955
167. Carrière C, et al. Gastroenterology (2011) pmid: 21699781
168. Park JK, et al. Biochem. Biophys. Res. Commun. (2011) pmid: 21329664
169. Burkhart DL, et al. Nat. Rev. Cancer (2008) pmid: 18650841
170. Knudsen ES, et al. Nat. Rev. Cancer (2008) pmid: 19143056
171. Berge EO, et al. Mol. Cancer (2010) pmid: 20594292
172. Giacinti C, et al. Oncogene (2006) pmid: 16936740
173. Otterson GA, et al. Proc. Natl. Acad. Sci. U.S.A. (1997) pmid: 9342358
174. Otterson GA, et al. Am. J. Hum. Genet. (1999) pmid: 10486322
175. Qin XQ, et al. Genes Dev. (1992) pmid: 1534305
176. Rubin SM, et al. Cell (2005) pmid: 16360038
177. Sun H, et al. Mol. Cell. Biol. (2006) pmid: 16449662
178. Chen Z, et al. Hum. Mutat. (2014) pmid: 24282159
179. Yun J, et al. Int J Ophthalmol (2011) pmid: 22553621
180. Houston SK, et al. Int Ophthalmol Clin (2011) pmid: 21139478
181. Ng AK, et al. Semin Radiat Oncol (2010) pmid: 19959033
182. Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315
183. Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033
184. Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100
185. Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633
186. Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850
187. Xu L, et al. Mol. Med. (2001) pmid: 11713371
188. Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564
189. Kim SS, et al. Nanomedicine (2015) pmid: 25240597
190. Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628
191. Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554
192. Moore et al., 2019; ASCO Abstract 5513
193. Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224
194. Oza et al., 2015; ASCO Abstract 5506
195. Lee J, et al. Cancer Discov (2019) pmid: 31315834
196. Méndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125
197. Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072
198. Gourley et al., 2016; ASCO Abstract 5571
199. Park H, et al. ESMO Open (2022) pmid: 36084396
200. Morton JP, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20018721
201. Scarpa A, et al. Am. J. Pathol. (1993) pmid: 8494051
202. Luo Y, et al. Pathol. Oncol. Res. (2013) pmid: 22782330
203. Iacobuzio-Donahue CA, et al. Clin. Cancer Res. (2012) pmid: 22896692
204. Macgregor-Das AM, et al. J Surg Oncol (2013) pmid: 22806689
205. Oshima M, et al. Ann. Surg. (2013) pmid: 23470568
206. Ottenhof NA, et al. Cell Oncol (Dordr) (2012) pmid: 22351431
207. Tsiambas E, et al. J BUON () pmid: 20414934
208. Ansari D, et al. Br J Surg (2011) pmid: 21644238
209. Grochola LF, et al. Pancreas (2011) pmid: 21404460
210. Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675
211. Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249
212. Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609
213. Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130
214. Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496
215. Yamada H, et al. Carcinogenesis (2007) pmid: 17690113
216. Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669
217. Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290
218. Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100
219. Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776
220. Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316
221. Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208
222. Lalloo F, et al. Lancet (2003) pmid: 12672316
223. Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713
224. Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837
225. Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838
226. Xie M, et al. Nat. Med. (2014) pmid: 25326804
227. Acuna-Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404
228. Severson EA, et al. Blood (2018) pmid: 29678827
229. Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212
230. Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320
231. Chabon JJ, et al. Nature (2020) pmid: 32269342
232. Razavi P, et al. Nat. Med. (2019) pmid: 31768066
233. Moreira et al., 2015; ASCO Abstract 315
234. Weinberg et al., 2020; AACR Abstract CT116
235. Javle MM, et al. BMC Cancer (2010) pmid: 20630061
236. Kordes S, et al. Invest New Drugs (2013) pmid: 22367239
237. Wolpin BM, et al. J. Clin. Oncol. (2009) pmid: 19047305
238. Tolcher AW, et al. Ann. Oncol. (2015) pmid: 25344362
239. Patterson et al., 2018; AACR Abstract 3891
240. Moroney J, et al. Clin. Cancer Res. (2012) pmid: 22927482
241. Reungwetwattana T, et al. J Thorac Oncol (2012) pmid: 22722792
242. Spindler KL, et al. Acta Oncol (2013) pmid: 23514584
243. Moulder S, et al. Ann. Oncol. (2015) pmid: 25878190